This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (10)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in this journal  Topic Collections  • Cerebrovascular Disease  • Stroke  • Alert me on articles by topic  Social Bookmarking   What's this?

Alexandre Balzano Maulaz, MD; Daniel C. Bezerra, MD; Patrik Michel, MD; Julien Bogousslavsky, MD

Arch Neurol. 2005;62:1217-1220.

Background  Aspirin, or acetylsalicylic acid, is widely used to prevent ischemic vascular disease. Clinical and experimental data suggest that a rebound effect occurs 4 or fewer weeks after interruption of aspirin therapy.

Objective  To study the discontinuation of aspirin therapy as a risk factor for ischemic stroke (IS).

Design  Case-control study.

Setting  Stroke unit.

Participants  Three hundred nine patients with IS or transient ischemic attack undergoing long-term aspirin treatment before their index event and 309 age-, sex-, and antiplatelet therapy–matched controls who had not had an IS in the previous 6 months.

Methods  We compared the frequency of aspirin therapy discontinuation during the 4 weeks before an ischemic cerebral event in patients and the 4 weeks before interview in controls.

Results  The 2 groups had a similar frequency of risk factors, except for coronary heart disease, which was more frequent in patients (36% vs 18%; P<.001). Aspirin use had been discontinued in 13 patients and 4 controls. Aspirin interruption yielded an odds ratio for IS/transient ischemic attack of 3.4 (95% confidence interval, 1.08-10.63; P<.005) after adjustment in a multivariable model.

Conclusions  These results highlight the importance of aspirin therapy compliance and give an estimate of the risk associated with the discontinuation of aspirin therapy in patients at risk for IS, particularly those with coronary heart disease.

Author Affiliations: Department of Neurology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Rebound Inflammation and the Risk of Ischemic Stroke After Discontinuation of Aspirin Therapy
Michal R. Pijak
Arch Neurol. 2006;63(2):300-301.
EXTRACT | FULL TEXT  

Rebound Inflammation and the Risk of Ischemic Stroke After Discontinuation of Aspirin Therapy—Reply
Alexandre B. Maulaz, Daniel C. Bezerra, Patrik Michel, and Julien Bogousslavsky
Arch Neurol. 2006;63(2):301.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Coagulation Concepts Update
O'Connor et al.
Am. J. Roentgenol. 2009;193:1656-1664.
ABSTRACT | FULL TEXT  

Prothrombotic and Hemorrhagic Effects of Aspirin
Aguejouf et al.
CLIN APPL THROMB HEMOST 2009;15:523-528.
ABSTRACT  

Safety of Short-Term Discontinuation of Antiplatelet Therapy in Patients With Drug-Eluting Stents
Eisenberg et al.
Circulation 2009;119:1634-1642.
ABSTRACT | FULL TEXT  

Adverse Events Associated With Stopping Clopidogrel After Acute Coronary Syndrome
Goyal and Punnam
JAMA 2008;299:2389-2389.
FULL TEXT  

Incidence of Death and Acute Myocardial Infarction Associated With Stopping Clopidogrel After Acute Coronary Syndrome
Ho et al.
JAMA 2008;299:532-539.
ABSTRACT | FULL TEXT  

Perioperative Stroke
Selim
NEJM 2007;356:706-713.
FULL TEXT  

Rebound Inflammation and the Risk of Ischemic Stroke After Discontinuation of Aspirin Therapy--Reply
Maulaz et al.
Arch Neurol 2006;63:301-301.
FULL TEXT  

Rebound Inflammation and the Risk of Ischemic Stroke After Discontinuation of Aspirin Therapy
Pijak
Arch Neurol 2006;63:300-301.
FULL TEXT